BIM 23B065

Drug Profile

BIM 23B065

Alternative Names: BIM23B065

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Class
  • Mechanism of Action Dopamine D2 receptor agonists; Somatostatin receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Acromegaly
  • Phase I Pituitary ACTH hypersecretion

Most Recent Events

  • 02 Jun 2017 Ipsen terminates a phase II trial in Acromegaly (In the elderly, In adults) in Belarus, Belgium, Bulgaria, Hungary, Serbia and Ukraine (NCT03045302)
  • 06 Oct 2016 Phase-II clinical trials in Acromegaly (In the elderly, In adults) in Hungary (SC) in October 2016 (EUDRACT2015-003868-37)
  • 01 Jan 2016 Phase-I clinical trials in Pituitary ACTH Hypersecretion in USA (SC) before January 2016 (Ipsen pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top